Skip to main content
Log in

Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy

  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Response to cytotoxic agents is assumed to be related to the concentration of drug achieved within tumour tissue. It is also often assumed that, given similar tissue concentrations of drug, normal tissues are less responsive to the same cytotoxic agents. This can partly be explained by the number of cells in normal tissues that are differentiated. These non dividing cells, in a stable testing phase of the cell cycle (Go) are less susceptible to cytotoxic damage. Little is actually known about the relationship between tumour drug concentrations and those in the tissue of the tumour-bearing organ. In this study, we compared doxorubicin concentrations in paried samples of tumour and normal breast tissue from 17 previously untreated women undergoing mastectomy. The relative cellularities of both specimens were estimated by measuring their DNA content. There was wide variation in intra-tumoural doxorubicin concentrations (range, 220–1,590 ng/g). Normal tissue also showed marked inter-patient variation (range, 81–1,000 ng/g). For a single patient the tumour drug concentrations were significantly higher than those in normal breast tissue (P<0.05), and tumour: normal tissue ratios ranged from 1.27 to 8.30. Where doxorubicin concentration was expressed in terms of the relative cellularity of the tissues, there was no significant difference between, drug concentrations in the tumour and those in normal breast tissue (tumour: normal ratios, 1.1: 1.8). There was a significant correlation (r=0.76,P<0.05) between peak serum values and tumour concentrations of drug. No correlation was found between drug concentrations achieved and the histological grade or oestrogen receptor status of the breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Amiel SA, Stewart JF, Earl HM, Knight RK, Rubens RD (1985) Adriamycin and mitomycin C as initial chemotherapy for advanced breast cancer. Eur J Cancer Clin Oncol 21: 1475

    Google Scholar 

  2. Arena E, D'Alessandro N, dusonchet L, Gebbia N, Gerbasi F, Palazzoadriano M, Raineri A, Rausa L, Tubaro E (1971) Analysis of the pharmacokinetic characteristics, pharmacological and chemotherapeutic activity of 14-hydroxydaunomycin (Adriamycin), a new drug endowed with an antitumour activity. Arzneim-Forsch 21: 1258–1263

    Google Scholar 

  3. Bachur NR, Hildebrand RC, Jaenke RS (1974) Adriamycin and daunorubicin disposition in the rabbit. J Pharmacol Exp Ther 191: 331–340

    Google Scholar 

  4. Beck WT, Mueller RJ, Tanzer LR (1979) Altered surface membrane glycoproteins in vinca alkaloid-resistant human leukaemic lymphoblasts. Cancer Res 39: 2070–2076

    Google Scholar 

  5. Bonadonna G, Monfardini S, De Lena M (1970) Phase I and preliminary phase II evaluation of Adriamycin. Cancer Res 30: 2572–2582

    Google Scholar 

  6. Blum RH, Carter SK (1974) Adriamycin — a new anticancer drug with significant clinical activity. Ann Intern Med 80:249–259

    Google Scholar 

  7. Carmo-Pereira J, Oliveira Costa F, Henriques E, Godinho F, Cantinho-Lopes MG, Sales-Luis A, Rubens RD (1987) A comparison of two doses of Adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br. J Cancer 56: 471–473

    Google Scholar 

  8. Chan KK, Cohen JL, Gross JF, Himmelstein KJ, Bateman JR, Lee Y-TN, Marlis AS (1978) Prediction of Adriamycin disposition in cancer patients using a physiologic pharmacokinetic model. Cancer Treat Rep 62: 1161–1171

    Google Scholar 

  9. Cummings J, McArdle CS (1986) Studies on the in vivo disposition of Adriamycin in human tumours which exhibit different responses to the drug. Br J Cancer 53: 835–838

    Google Scholar 

  10. Cummings J, Stuart JFB, Calman KC (1984) Determination of Adriamycin, Adriamycinol and their 7-deoxyglycones in human serum by high-performance liquid chromatography. J Chromatogr 311: 125–133

    Google Scholar 

  11. Cummings J, Merry S, Willimott N (1986) Disposition kinetics of Adriamycin, Adriamycinol and their 7-deoxyaglycones in A/CR mice bearing a sub-cutaneously growing ridgeway osteogenic sarcoma (ROB). Eur J Cancer Clin Oncol 22: 451–460

    Google Scholar 

  12. Dano K (1973) Active outward transport of daunomycin in Ehrlich ascites tumour cells. Biochim Biophys Acta 323: 466

    Google Scholar 

  13. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I (1987) Expression of a multidrug-resistance gene in human tumours and tissues. Proc Natl Acad Sci USA 84: 265–269

    Google Scholar 

  14. Gunven P, Theve NO, Peterson C (1986) Serum and tissue concentrations of doxorubicin after IV administration of doxorubicin or doxorubicin-DNA complex to patients with gastrointestinal cancer. Cancer Chemother Pharmacol 17: 153–156

    Google Scholar 

  15. Katzenellenbogen BS, Leake RE (1974) Burton method for DNA analysis. J Endocrinol 63: 439–449

    Google Scholar 

  16. Lee Y-TN, Chan KK, Harris PA, Cohen JL (1980) Distribution of Adriamycin in cancer patients. Tissue uptakes, plasma concentration after IV and hepatic IA administration. Cancer 45: 2231–2239

    Google Scholar 

  17. Ling V, Thomson LH (1973) J Cell Physiol 83: 103–116

    Google Scholar 

  18. O'Bryan RM, Luce JK, Talley RW (1973) Phase II evaluation of Adriamycin in human neoplasia. Cancer 32: 1–8

    Google Scholar 

  19. O'Bryan RM, Baker LH, Gottleib JE (1977) Dose response evaluation of Adriamycin in human neoplasia. Cancer 39: 1940

    Google Scholar 

  20. Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myes CE, Young RC (1979) Pharmacokinetics of Adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 39: 3209

    Google Scholar 

  21. Rossi C, Gasparini G, Canobbio L, Galigioni E, Volpe R, Candiani E, Toffoli F, D'Incalci M (1987) Doxorubicin distribution in human breast cancer. Cancer Treat Rep 71: 1221

    Google Scholar 

  22. Schwartz HS (1973) A fluorimetric assay for daunomycin and Adriamycin in animal tissues. Biochem Med 7: 396

    Google Scholar 

  23. Siegfried JA, Tritton TR, Sartorelli AC (1983) Comparison of anthracycline concentrations in 5180 cell-lines of varying sensitivity. Eur J Cancer Clin Oncol 19: 1133–1141

    Google Scholar 

  24. Smithe HS, Lippmann ME, Hiller AJ, Stampfer MR, Hackett AJ (1985) Response to doxorubicin of cultured normal and cancerous human mammary epithelial cells. J Natl Cancer Inst 74 (2): 341–347

    Google Scholar 

  25. Steiner R, Stewart JF, Cantwell BJM, Minton MJ, Knight RK, Rubens RD (1983) Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer. Eur J Cancer Clin Oncol 19: 1553

    Google Scholar 

  26. Yesair DW, Schwartzbach E, Shuck D (1972) Comparative pharmacokinetics of daunomycin and Adriamycin in several animal species. Cancer Res 32: 1177–1182

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stallard, S., Morrison, J.G., George, W.D. et al. Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy. Cancer Chemother. Pharmacol. 25, 286–290 (1990). https://doi.org/10.1007/BF00684887

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00684887

Keywords

Navigation